NIGHTSTAR THERAPEUTICS PLC Research and Development Expense
NIGHTSTAR THERAPEUTICS PLC reported Research and Development Expense of $8.90 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2019-05-10
- NIGHTSTAR THERAPEUTICS PLC research and development expense for the quarter ending 2019-03-31 was $8.90M, a 46.73% increase year-over-year.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for the quarter ending 2018-12-31 was $9.62M, a 5.91% decline year-over-year.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for the quarter ending 2018-09-30 was $7.84M, a 96.96% increase year-over-year.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for the quarter ending 2018-06-30 was $8.05M, a 127.33% increase year-over-year.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for fiscal 2018 was $31.59M, a 54.06% increase from fiscal 2017.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for fiscal 2017 was $20.50M, a 101.69% increase from fiscal 2016.
- NIGHTSTAR THERAPEUTICS PLC research and development expense for fiscal 2016 was $10.16M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2019-03-31 | $8.90M 10-Q · filed 2019-05-10 | $18.52M derived: sum of 2 quarters · filed 2019-05-10 | $26.37M derived: sum of 3 quarters · filed 2019-05-10 | $34.42M derived: sum of 4 quarters · filed 2019-05-10 |
| 2018-12-31 | $9.62M 10-K · filed 2019-03-18 | $17.47M derived: sum of 2 quarters · filed 2019-03-18 | $25.52M derived: sum of 3 quarters · filed 2019-03-18 | $31.59M 10-K · filed 2019-03-18 |
| 2018-09-30 | $7.84M 10-K · filed 2019-03-18 | $15.90M derived: sum of 2 quarters · filed 2019-03-18 | $21.96M 6-K · filed 2018-11-20 | $32.19M derived: sum of 4 quarters · filed 2019-05-10 |
| 2018-06-30 | $8.05M 10-K · filed 2019-03-18 | $14.12M 6-K · filed 2018-08-15 | $24.34M derived: sum of 3 quarters · filed 2019-05-10 | $28.33M derived: sum of 4 quarters · filed 2019-05-10 |
| 2018-03-31 | $6.06M 10-Q · filed 2019-05-10 | $16.29M derived: sum of 2 quarters · filed 2019-05-10 | $20.27M derived: sum of 3 quarters · filed 2019-05-10 | $23.82M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $10.23M 10-K · filed 2019-03-18 | $14.21M derived: sum of 2 quarters · filed 2019-03-18 | $17.75M derived: sum of 3 quarters · filed 2019-03-18 | $20.50M 10-K · filed 2019-03-18 |
| 2017-09-30 | $3.98M 10-K · filed 2019-03-18 | $7.53M derived: sum of 2 quarters · filed 2019-03-18 | $10.28M 6-K · filed 2018-11-20 | |
| 2017-06-30 | $3.54M 10-K · filed 2019-03-18 | $6.29M 6-K · filed 2018-08-15 | ||
| 2017-03-31 | $2.75M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $10.16M 10-K · filed 2019-03-18 | |||
| 2015-12-31 | $7.17M 20-F · filed 2018-04-03 |